john_harris

OBN appoints Dr John Harris as chief executive

pharmafile | December 4, 2015 | Appointment | Medical Communications, Sales and Marketing OBN 

OBN, the membership organisation supporting the UK’s emerging life sciences companies, has appointed Dr John Harris as its new chief executive, replacing Ross Sommerville. 

Dr John Harris comments: “I am delighted to be joining OBN as CEO; it has a fantastic purpose and a very impressive membership base. I am thrilled to be given this role and very much looking forward to working with OBN’s member companies, its experienced team and a range of stakeholders to continue growing a vibrant life sciences sector in the UK.” 

Currently Dr Harris is delivering business and export advice to UK trade and industry clients, assisting life science companies on growth strategies both domestically and abroad. His most recent appointment was managing partner of Qube Associates, a specialist consultancy focusing on science-based SMEs.

Previous appointments include managing director of IPS specials/Vertical Pharma, managing director of Key Organics, managing director of Synerga and chief executive of TraceTag International. 

Advertisement

Dr Harris holds a BSc (Hons) in Biology from the University of Salford, a PhD in plant pathology and biochemistry from the University of Southampton and a MBA from the University of Surrey.  

David Laskow-Pooley, chairman of OBN, says: “We are very excited and pleased to have Dr Harris join OBN to continue and lead our work supporting the development of emerging life sciences companies in the UK. Dr Harris will bring enormous skills and knowledge to continue our growth.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content